Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Sterile solutions remain single-use and lack preservatives for extended vial use
This could include low-alcohol, low-sugar, or even functional beverages that incorporate health benefits
Importantly, expression of the receptor FPR2 has been confirmed in synovial fibroblasts from rheumatoid arthritis patients (149, 150)
According to this criterion, 39 of the 45 patients (86.6%) were found to be hyperinsulinemic and 6 (13.4%) normoinsulinemic